Target Name: OSER1
NCBI ID: G51526
Review Report on OSER1 Target / Biomarker Content of Review Report on OSER1 Target / Biomarker
OSER1
Other Name(s): Oxidative stress-responsive serine-rich protein 1 | oxidative stress-responsive protein 1 | Perit1 | oxidative stress-responsive 1 | Peroxide-inducible transcript 1 protein | oxidative stress responsive serine rich 1 | dJ1183I21.1 | OSER1_HUMAN | Peroxide-inducible transcript 1 | Osr1 | Oxidative stress responsive serine rich 1 | Oxidative stress-responsive protein 1 | peroxide-inducible transcript 1 protein | C20orf111 | HSPC207

OSER1: A Potential Drug Target and Biomarker

OSER1, also known as oxidative stress-responsive serine-rich protein 1, is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell stress responses, and has been implicated in a wide range of physiological processes, including cell survival, inflammation, and stress-induced diseases.

In recent years, researchers have been increasingly interested in OSER1 as a potential drug target or biomarker. This is because the protein has been shown to play a crucial role in a variety of diseases, including cancer, neurodegenerative diseases, and chronic obstructive pulmonary disease (COPD).

One of the key reasons for the interest in OSER1 is its ability to interact with a variety of different proteins, including transcription factors, DNA-binding proteins, and signaling molecules. This makes it a potentially promising target for drugs that can modulate its activity and have a therapeutic effect on disease.

In addition to its potential as a drug target, OSER1 has also been shown to be a valuable biomarker for a number of different diseases. For example, researchers have used the protein to diagnose and monitor the progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. They have also used it to assess the effectiveness of anti-inflammatory drugs in treating inflammatory conditions, such as rheumatoid arthritis and colitis.

Another promising application of OSER1 is its potential as a therapeutic agent for cancer. Because the protein is involved in a wide range of cellular processes that are critical for cancer cell growth and survival, researchers have been interested in using it as a target for cancer therapies. For example, studies have shown that inhibiting OSER1 can be an effective way to inhibit the growth and survival of cancer cells.

In addition to its potential as a drug target and biomarker, OSER1 is also of interest to researchers because of its ability to regulate cell stress responses. This is important because chronic stress can have a negative impact on the health and function of tissues and organs, and because many diseases are caused by chronic stress.

For example, research has shown that OSER1 plays a key role in regulating the stress response in tissues that are exposed to chronic stress, such as the brain and the immune system. This means that OSER1 may be a useful target for drugs that can modulate its activity and help to reduce the negative effects of chronic stress.

Overall, OSER1 is a protein that has the potential to be a drug target or biomarker for a wide range of diseases. Its ability to interact with a variety of different proteins, as well as its involvement in cell stress responses, make it an attractive target for researchers who are looking for new ways to treat and prevent disease.

Protein Name: Oxidative Stress Responsive Serine Rich 1

The "OSER1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OSER1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OSER1-DT | OSGEP | OSGEPL1 | OSGEPL1-AS1 | OSGIN1 | OSGIN2 | OSM | OSMR | OSMR-DT | OSR1 | OSR2 | OST4 | OSTC | OSTCP1 | OSTF1 | OSTF1P1 | OSTM1 | OSTM1-AS1 | OSTN | OSTN-AS1 | OTC | OTOA | OTOAP1 | OTOF | OTOG | OTOGL | OTOL1 | OTOP1 | OTOP2 | OTOP3 | OTOR | OTOS | OTP | OTUB1 | OTUB2 | OTUD1 | OTUD3 | OTUD4 | OTUD5 | OTUD6A | OTUD6B | OTUD6B-AS1 | OTUD7A | OTUD7B | OTULIN | OTULINL | OTX1 | OTX2 | OTX2-AS1 | OVAAL | OVCA2 | OVCH1 | OVCH1-AS1 | OVCH2 | OVGP1 | OVOL1 | OVOL1-AS1 | OVOL2 | OVOL3 | OVOS2 | OXA1L | OXA1L-DT | OXCT1 | OXCT1-AS1 | OXCT2 | OXCT2P1 | OXER1 | OXGR1 | OXLD1 | OXNAD1 | OXR1 | OXSM | OXSR1 | OXT | OXTR | Oxysterol-binding protein | Oxysterols receptor LXR | P2RX1 | P2RX2 | P2RX3 | P2RX4 | P2RX5 | P2RX5-TAX1BP3 | P2RX6 | P2RX6P | P2RX7 | P2RY1 | P2RY10 | P2RY10BP | P2RY11 | P2RY12 | P2RY13 | P2RY14 | P2RY2 | P2RY4 | P2RY6 | P2RY8 | P2X Receptor | P2Y purinoceptor | P3H1